Icariin delays homocysteine-induced endothelial cellular senescence involving activation of the PI3K/AKT-eNOS signaling pathway

Pharm Biol. 2013 Apr;51(4):433-40. doi: 10.3109/13880209.2012.738332. Epub 2013 Jan 22.

Abstract

Context: Homocysteine-induced endothelial cellular senescence may contribute to some cardiovascular disorders. Icariin (ICA), a flavonoid derived from Epimedium sagittatum Maxim. (Berberidaceae), has been reported to increase production of nitric oxide (NO) and reduce reactive oxygen species (ROS) levels in human umbilical vein endothelial cells (HUVECs).

Objective: To observe the effects of ICA on homocysteine-induced senescence and the underlying mechanisms in HUVECs.

Materials and methods: ICA at concentrations of 0.1, 1, and 5 μM was added into homocysteine pretreated HUVECs. Cellular senescence was assayed by senescence-associated β-galactosidase (SA-β-gal) staining and cumulative population doublings (CPDs). ICA (5 μM) was given orally to homocysteine-treated rats, luminal surface of aortic artery of rats was subjected to SA-β-gal staining. Protein expression was measured by western blot.

Results: Homocysteine significantly increased cellular senescence both in vitro and in vivo. After treatment by ICA, the percentage of SA-β-gal-positive cells, and the ROS level significantly decreased. The CPDs were partially restored. ICA also significantly reduced the mean density of SA-β-gal staining in vivo. We found that NO production and phosphorylation of AKT, ERK, and endothelial NO synthase (eNOS) were elevated by ICA in HUVECs. Furthermore, the increased level of NO production was fully abolished by the phosphatidylinositol-3-kinase (PI3K) inhibitor wortmannin. The mitogen-activated protein kinase (MEK) inhibitor PD98059, which can inhibit phosphorylation of ERK, did not show this ability.

Discussion and conclusion: Our results indicate that ICA delays homocyteine-induced endothelial senescence in vitro and in vivo. Activation of PI3K/Akt-eNOS-dependent signaling pathway may be responsible for this efficacy of ICA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Biomarkers / metabolism
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Cellular Senescence / drug effects*
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Flavonoids / administration & dosage
  • Flavonoids / pharmacology*
  • Homocysteine / metabolism*
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / enzymology
  • Human Umbilical Vein Endothelial Cells / pathology
  • Humans
  • Male
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / metabolism*
  • Phosphatidylinositol 3-Kinase / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Rats
  • Rats, Wistar
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects*
  • Time Factors
  • beta-Galactosidase / metabolism

Substances

  • Biomarkers
  • Flavonoids
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase Inhibitors
  • Reactive Oxygen Species
  • Homocysteine
  • Nitric Oxide
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt
  • beta-Galactosidase
  • icariin